Towa Pharmaceutical Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 5 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Major Holders
Updated 2026/01/11| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Brown Capital Mgmt Mutual Fd.s-Brown Capital Mgmt Intl Small Company F
|
2.4M | +3.33% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
355.2K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
225.5K | 0.00% | |
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
226.1K | +42.83% | |
|
Goldman Sachs TRT-Goldman Sachs Intl Small Cap Insights Fd.
|
196.4K | 0.00% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
|
154.3K | +8.05% |
Dividend History 1Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥80 | +33.3% |
| 2024 | ¥60 | 0.0% |
| 2023 | ¥60 | -4.8% |
| 2022 | ¥63 | +28.6% |
| 2021 | ¥49 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥165,615M | ¥208,859M | ¥227,934M | ¥259,594M |
| Gross Profit | ¥70,185M | ¥72,713M | ¥81,383M | ¥94,729M |
| Operating Income | ¥19,205M | ¥5,514M | ¥17,648M | ¥23,243M |
| Pretax Income | ¥22,476M | ¥5,240M | ¥25,406M | ¥27,957M |
| Net Income | ¥15,914M | ¥2,201M | ¥16,173M | ¥18,986M |
| EPS | ¥316.19 | ¥44.72 | ¥328.59 | ¥385.71 |
| Operating Margin | 11.60% | 2.64% | 7.74% | 8.95% |
| Balance Sheet | ||||
| Total Assets | ¥332,097M | ¥371,347M | ¥430,653M | ¥470,823M |
| Total Equity | ¥132,168M | ¥136,893M | ¥155,892M | ¥171,624M |
| Total Liabilities | ¥199,929M | ¥234,454M | ¥274,761M | ¥299,199M |
| Cash | ¥32,830M | ¥24,257M | ¥29,650M | ¥45,471M |
| Interest-bearing Debt | ¥140,701M | ¥161,518M | ¥203,308M | ¥230,983M |
| Equity Ratio | 39.80% | 36.86% | 36.20% | 36.45% |
| D/E Ratio | 1.06 | 1.18 | 1.30 | 1.35 |
| Cash Flow | ||||
| Operating CF | ¥22,129M | ¥2,544M | ¥8,212M | ¥23,401M |
| Investing CF | -¥59,729M | -¥30,284M | -¥40,394M | -¥31,287M |
| Financing CF | ¥46,540M | ¥17,481M | ¥35,407M | ¥21,567M |
| Free CF | ¥8,553M | -¥27,925M | -¥31,113M | -¥7,822M |
| Efficiency | ||||
| ROE | 12.04% | 1.61% | 10.37% | 11.06% |
| ROA | 4.79% | 0.59% | 3.76% | 4.03% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 4553
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥3,880
Rating Score: - (Based on 5 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from Tablets, Capsules, Injectable, Patches, eye drops, and other products. It also offers IT service related to healthcare; disease risk testing services; and quasi drugs. In addition, the company is involved in research and development and production of active pharmaceutical ingredients, intermediates, support business; and planning, development and OEM manufacturing of health foods, pharmaceuticals, general foods, and other miscellaneous merchandizes. The company was founded in 1951 and is headquartered in Osaka, Japan.
